Efficacy evaluation of drug-coated balloon therapy in treating patients with atherosclerotic occlusive disease of lower extremity
-
摘要:目的 探讨药物涂层球囊治疗下肢动脉粥样硬化闭塞性疾病的疗效。方法 回顾性分析接受药物涂层球囊治疗的38例下肢动脉硬化闭塞性疾病患者的术前、术中以及术后随访资料。结果 本研究38例患者患肢血管均再通成功，术后随访期间均未发生与手术相关或其他原因导致的死亡、截肢、靶病变血栓形成等并发症，无需要手术再干预患者，随访率100.00%。术后6个月、1年的Ⅰ期通畅率为84.21%、73.68%。所有患者术后不同时点的踝肱指数(ABI)、行走距离、Rutherford分级均较术前显著改善(P < 0.05)。结论 药物涂层球囊治疗下肢动脉粥样硬化闭塞性疾病的疗效显著。Abstract:Objective To explore the efficacy of drug-coated balloon therapy in treatment of patients with atherosclerotic occlusive disease of lower extremity.Methods The preoperative, intra-operative and postoperative follow-up data of 38 patients with arteriosclerosis occlusive disease of lower extremity treated by drug-coated balloon therapy were retrospectively analyzed.Results All the 38 patients had successful revascularization of affected limbs. During the follow-up period, no complications such as death, amputation, thrombosis of target lesions and other complications associated with surgery occurred. No patients with further intervention were observed, and the follow-up rate was 100.00%. The patency rate of stage Ⅰ was 84.21% and 73.68% at 6 months and 1 year after operation. Ankle Brachial Index (ABI), walking distance and Rutherford grading of all patients at different time points after operation were significantly improved when compared with those before operation (P < 0.05).Conclusion Drug-coated balloon therapy is effective in the treatment of patients with atherosclerotic occlusive diseases of lower extremity.
-
-
表 1 药物涂层球囊手术前后ABI、行走距离及Rutherford分级比较(x±s)
指标 时点 水平 95% CI 踝肱指数 术前 0.44±0.12 0.39~0.47 术后第1天 0.86±0.15* 0.80~0.90 术后6个月 0.78±0.16* 0.74~0.84 术后1年 0.76±0.14* 0.71~0.80 行走距离/m 术前 108.55±11.68 71.85~145.26 术后6个月 789.47±104.10* 456.15~1 122.80 术后1年 668.68±68.57* 383.19~954.18 Rutherford分级 术前 4(4，5) — 术后第1天 3(2，3)* — 术后6个月 3(2，3)* — 术后1年 3(2，3)* — 患者术后第1天未能下地行走，未统计行走距离; 患者Rutherford分级以中位数表示。与术前比较, *P < 0.05。 
下载: 导出CSV
-
[1] Willey J, Mentias A, Vaughan-Sarrazin M, et al. Epidemiology of lower extremity peripheral artery disease in veterans[J]. J Vasc Surg, 2018, 68(2): 527-535. doi: 10.1016/j.jvs.2017.11.083
[2] Nehler M R, Duval S, Diao L H, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population[J]. J Vasc Surg, 2014, 60(3): 686-695. doi: 10.1016/j.jvs.2014.03.290
[3] Kibrik P, Victory J, Patel R, et al. A real-world experience of drug eluting and non-drug eluting stents in lower extremity peripheral arterial disease[J]. Vascular, 2019: 17085381. http://www.sciencedirect.com/science/article/pii/S0741521418311637
[4] Ramaiah V, Gammon R, Kiesz S, et al. Midterm outcomes from the TALON Registry: treating peripherals with SilverHawk: outcomes collection[J]. J Endovasc Ther, 2006, 13(5): 592-602. doi: 10.1583/05-1780MR.1
[5] Shammas N W, Dippel E J, Coiner D, et al. Preventing lower extremity distal embolization using embolic filter protection: results of the PROTECT registry[J]. J Endovasc Ther, 2008, 15(3): 270-276. doi: 10.1583/08-2397.1
[6] Schlager O, Gschwandtner M E, Willfort-Ehringer A, et al. Drug coated balloons in the superficial femoral artery[J]. J Cardiovasc Surg (Torino), 2018, 59(1): 60-69.
[7] Schneider P A, Laird J R, Doros G, et al. Mortality not correlated with paclitaxel exposure: an independent patient-level meta-analysis of a drug-coated balloon[J]. J Am Coll Cardiol, 2019, 73(20): 2550-2563. doi: 10.1016/j.jacc.2019.01.013
[8] Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-2128. doi: 10.1016/S0140-6736(12)61728-0
[9] Jaff M R, White C J, Hiatt W R, et al. An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: A supplement to the inter-society consensus for the management of peripheral arterial disease (TASC Ⅱ): The TASC steering committee[J]. Catheter Cardiovasc Interv, 2015, 86(4): 611-625. doi: 10.1002/ccd.26122
[10] Cortese B, Berti S, Biondi-Zoccai G, et al. Drug-coated balloon treatment of coronary artery disease: a position paper of the Italian Society of Interventional Cardiology[J]. Catheter Cardiovasc Interv, 2014, 83(3): 427-435. doi: 10.1002/ccd.25149
[11] Schneider P A, Laird J R, Tepe G, et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN. PACT SFA randomized trial[J]. Circ Cardiovasc Interv, 2018, 11(1): e005891. http://europepmc.org/articles/PMC5771683/
[12] Micari A, Nerla R, Vadalà G, et al. 2-year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-long study[J]. JACC Cardiovasc Interv, 2017, 10(7): 728-734. doi: 10.1016/j.jcin.2017.01.028
[13] Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN. PACT SFA randomized trial[J]. Circulation, 2015, 131(5): 495-502. doi: 10.1161/CIRCULATIONAHA.114.011004
[14] Cortese B, Granada J F, Scheller B, et al. Drug-coated balloon treatment for lower extremity vascular disease intervention: an international positioning document[J]. Eur Heart J, 2016, 37(14): 1096-1103. doi: 10.1093/eurheartj/ehv204
[15] Dake M D, Ansel G M, Jaff M R, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results[J]. Circ Cardiovasc Interv, 2011, 4(5): 495-504. doi: 10.1161/CIRCINTERVENTIONS.111.962324
[16] Dake M D, Ansel G M, Jaff M R, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies[J]. J Am Coll Cardiol, 2013, 61(24): 2417-2427. doi: 10.1016/j.jacc.2013.03.034
[17] Scheinert D, Duda S, Zeller T, et al. The LEVANT Ⅰ (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty[J]. JACC Cardiovasc Interv, 2014, 7(1): 10-19. doi: 10.1016/j.jcin.2013.05.022
[18] Bausback Y, Willfort-Ehringer A, Sievert H, et al. Six-month results from the initial randomized study of the ranger paclitaxel-coated balloon in the femoropopliteal segment[J]. J Endovasc Ther, 2017, 24(4): 459-467. doi: 10.1177/1526602817710770
[19] Steiner S, Willfort-Ehringer A, Sievert H, et al. 12-Month Results From the First-in-Human Randomized Study of the Ranger Paclitaxel-Coated Balloon for Femoropopliteal Treatment[J]. JACC Cardiovasc Interv, 2018, 11(10): 934-941. doi: 10.1016/j.jcin.2018.01.276
[20] Albrecht T, Speck U, Baier C, et al. Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine[J]. Invest Radiol, 2007, 42(8): 579-585. doi: 10.1097/RLI.0b013e31804f5a60
-
期刊类型引用(12)
1. 毕富玺，闫颖，马静. 基于脑肠轴理论探讨针刺治疗肾阴虚型绝经综合征伴焦虑障碍的临床疗效. 天津中医药. 2024(06): 754-758 . 
百度学术
2. 鲁芳. 针灸加耳穴贴压结合雌二醇片治疗更年期综合征疗效观察. 实用中医药杂志. 2024(09): 1799-1801 . 百度学术
3. 徐莹. 柴胡桂枝龙骨牡蛎汤加减结合针灸治疗不寐症的临床效果分析. 内蒙古中医药. 2024(11): 73-75 . 百度学术
4. 韩倩楠，陈必慧，朱海利. 围绝经期女性失眠的中西医治疗思路比较. 海南医学. 2023(01): 148-152 . 百度学术
5. 张燕，高嘉良，夏普. 柴胡桂枝龙骨牡蛎汤治疗心脏神经官能症临床观察. 深圳中西医结合杂志. 2023(18): 34-37 . 百度学术
6. 沈晓桦，卢根娣，蒋国静，胡丽，谈晓红. 引阳入阴推拿对剖宫产后心脾两虚证产妇睡眠障碍及负性情绪的影响. 实用临床医药杂志. 2022(09): 54-58 . 本站查看
7. 郭中建. 柴胡加龙骨牡蛎汤治疗永久性房颤伴失眠患者的效果. 中国民康医学. 2022(13): 77-79 . 百度学术
8. 李玉舸. 柴胡龙骨牡蛎汤加减治疗围绝经期失眠的临床研究. 医学食疗与健康. 2022(15): 33-35+193 . 百度学术
9. 冉固生，王毅. 酸枣仁汤加味结合针灸治疗围绝经期失眠临床研究. 河南中医. 2022(11): 1644-1647 . 百度学术
10. 王春华，朱人杰，董君伟. 鹿角龟芍汤联合盐酸帕罗西汀治疗围绝经期抑郁症的效果及对神经递质、生殖内分泌激素的影响. 临床误诊误治. 2022(11): 41-46 . 百度学术
11. 王鸣瑞，方朝晖，韩辉，丁小娟. 益肝血合酸枣仁汤加减治疗围绝经期妇女失眠对性激素水平及睡眠质量的影响. 湖南师范大学学报(医学版). 2021(04): 9-13 . 百度学术
12. 陈淼，史筱笑，安冬青. 桂枝汤类方治疗心系疾病的Meta分析. 河南中医. 2021(12): 1807-1814 . 百度学术
其他类型引用(8)
计量
- 文章访问数:
- HTML全文浏览量:
- PDF下载量:
- 被引次数: 20
苏公网安备 32100302010246号